Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give a written, signed and dated informed consent~* Subjects with atopic dermatitis who have participated in and completed 16 weeks of treatment in CZPL389A2203 study.~* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, diary completion and other study procedures.~Exclusion Criteria:~* Inability to use TCS and/or TCI due to history of important side effects of topical medication (e.g., intolerance or hypersensitivity reactions).~* Treatment discontinued subject from CZPL389A2203 study.~* Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis disease activity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZPL389 30mg (Type: EXPERIMENTAL): 30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
- ZPL389 50mg (Type: EXPERIMENTAL): 50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study

Based on this trial design, predict the completion outcome and termination type (if applicable).